Carlos F. A.
- Country
- Spain
- Department
- Servicio de Oncología
Research Overview
- Phase 3 Randomized, Double-blind, Placebo-controlled Study of Apalutamide and GnRH Agonist in High-risk Localized or Locally Advanced Prostate Cancer with Primary Radiation Therapy
- Evaluation of Apalutamide in Non-Metastatic Castration-Resistant Prostate Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial
Data & Insights
Has run more than one trial at 5 of 104 partner sites.
Specializations
Oncology Focus
The investigator specializes in treating high-risk and locally advanced prostate cancer, with particular emphasis on developing therapeutic approaches for challenging cases.
- Localized prostate cancer management
- Advanced prostate cancer treatments
- High-risk cancer interventions
Their expertise includes evaluating novel therapeutic approaches for prostate cancer patients requiring primary radiation therapy.
Therapeutic Expertise
The investigator focuses on implementing combination therapy approaches, particularly integrating hormonal treatments with radiation therapy for prostate cancer.
- Radiation therapy protocols
- Hormone therapy applications
- Multimodal treatment strategies
Their work encompasses the evaluation of treatment efficacy in complex prostate cancer cases requiring comprehensive therapeutic approaches.
Diagnostic Innovation
The investigator employs advanced imaging techniques including PSMA-PET imaging and conventional imaging methods for cancer assessment and treatment monitoring.
- Metastasis-free survival assessment
- Advanced imaging applications
- Treatment response monitoring
Their expertise includes utilizing sophisticated imaging technologies for precise cancer evaluation and treatment planning.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.